Advertisement

Topics

Institut Gustave Roussy Company Profile

06:27 EDT 24th September 2017 | BioPortfolio

The Institut Gustave Roussy (IGR, Villejuif, France), European leading Comprehensive Cancer Center, is a non profit academic entity belonging to the French public hospital service and that is authorized to receive donations and legacies. IGR is a center wholly patient-oriented with a global expertise and the mission to fight cancer. Located South of Paris on a single site, IGR employs 2,300 professionals working in care, research and teaching. Some IGR figures: 385 beds and places for day-cases, 207 certified physicians, 887 professional caregivers, 151,000 consultations and 43,000 patients cared per year, 14 basic research units, 300 research scientists, and 2800 students, researchers and physicians trained per year. www.igr.fr


News Articles [82 Associated News Articles listed on BioPortfolio]

Researchers uncover novel mechanism involved in cancer cell migration

Supervised by Guillaume Montagnac, Inserm research leader at Gustave Roussy, in collaboration with the Institut Curie and the Institut de Myologie, this research, is published in the 16th June issue o...

Dr. William Li Presenting at First International Rethinking Cancer Meeting at European Cancer Centre Gustave Roussy in Paris, France

CAMBRIDGE, Mass., Sept. 20, 2017 /PRNewswire-USNewswire/ -- The Angiogenesis Foundation announced today its President and Medical Director, Dr. William Li, will present new groundbreaking sc...

Discovery of a new mechanism involved in the migration of cancer cells

(Comprehensive Cancer Centre Gustave Roussy) A team of young French researchers has discovered a new mechanism which facilitates cell migration. On the surface of its membrane, the cell develops multi...

(3/6) ASCO 2017: STAMPEDE data

Section 3 - STAMPEDE Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA) chairs a discussion with Prof Karim Fizazi (Department of Cancer Medicine, Institut Gustave Roussey, France...

(2/6) ASCO 2017: LATITUDE data

Section 2 - LATITUDE Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA) chairs a discussion with Prof Karim Fizazi (Department of Cancer Medicine, Institut Gustave Roussey, France...

(1/6) ASCO 2017: Expert discussion on the latest in prostate cancer

Section 1 - Introduction Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA) chairs a discussion with Prof Karim Fizazi (Department of Cancer Medicine, Institut Gustave Roussey, Fr...

(3/6) ASCO 2017: Expert discussion on the latest in prostate cancer

Section 3 - STAMPEDE Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA) chairs a discussion with Prof Karim Fizazi (Department of Cancer Medicine, Institut Gustave Roussey, France...

(2/6) ASCO 2017: Expert discussion on the latest in prostate cancer

Section 2 - LATITUDE Dr Neal Shore (Carolina Urologic Research Center, South Carolina, USA) chairs a discussion with Prof Karim Fizazi (Department of Cancer Medicine, Institut Gustave Roussey, France...

Drugs and Medications [0 Results]

None

PubMed Articles [19 Associated PubMed Articles listed on BioPortfolio]

Everolimus Versus Axitinib as Second-line Therapy in Metastatic Renal Cell Carcinoma: Experience From Institut Gustave Roussy.

Everolimus (E) and axitinib (A) have been standard treatments for patients with metastatic renal cell carcinoma after failure of first-line therapy (1L) with vascular endothelial growth factor-targete...

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score).

Life expectancy evaluation is crucial when selecting patients who may benefit from phase I studies. The Royal Marsden Hospital (RMH) prognostic score, based on three objective variables (number of met...

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system.

Despite considerable progress in hematological malignancies (HM) biology during the last decades, translation into clinical benefit remains a major challenge. To improve patient selection and identify...

Marginal Bone Loss Around Early-Loaded SLA and SLActive Implants: Radiological Follow-Up Evaluation Up to 6.5 Years.

The aim of this study was to compare marginal bone loss around early-loaded SLA and SLActive tissue-level implants (Straumann Dental Implants; Institut Straumann AG, Basel, Switzerland) after a mean o...

Diagnostic Performance of Ultrasound-Guided Fine-Needle Aspiration of Nonpalpable Breast Lesions in a Multidisciplinary Setting: The Institut Curie's Experience.

To assess the diagnostic performance of ultrasound-guided fine-needle aspiration (USFNA) in nonpalpable breast lesions (NPBLs) in a multidisciplinary setting.

Clinical Trials [24 Associated Clinical Trials listed on BioPortfolio]

Functional Magnetic Resonance Imaging for High Throughput Curietherapy Planning in Prostate Cancer

Merge the data of ultrasound with that of the anatomical and functional MRI is necessary since the high dose rate Curietherapy is carried out under ultrasound guidance. The investigators w...

Bergonie Institut Profiling : Fighting Cancer by Matching Molecular Alterations and Drugs in Early Phase Trials

This is a biology driven, monocentric study designed to identify actionable molecular alterations in cancer patients with advanced disease. In this trial, high throughput analysis will be...

Institut Paoli Calmettes Myelodysplastic Syndromes Database

Database of Institut Paoli-Calmettes patients diagnosed with Myelodysplastic Syndromes

Study to Validate a Model of Surgical Deescalation in Atypicals Breast Lesions

Routine screening mammography has increased the non-palpable suspicious lesion detection rate, requiring histopathological evaluation. The discovery of atypical lesions on the breast biops...

Trial Evaluating Maintenance Olaparib in Patients With Platinum-sensitive Advanced Non-small Cell Lung Cancer

This is a multicentre randomised double-blind phase II trial, sponsored by Gustave Roussy and involving one French center as well as the Spanish Lung Cancer Group (≈20 centers of the SLC...

Companies [40 Associated Companies listed on BioPortfolio]

Institut Gustave-Roussy

The Institute Gustave-Roussy is a non-profit private institution, exclusively devoted to oncology.It is part of the French public hospital system.State-approved, it is authorised to receive donations ...

Institut Gustave Roussy

The Institut Gustave Roussy (IGR, Villejuif, France), European leading Comprehensive Cancer Center, is a non profit academic entity belonging to the French public hospital service...

WIN Consortium

The WIN Consortium (www.winconsortium.org) is a joint initiative of Institut Gustave Roussy (France) and University of Texas - MD Anderson Cancer Center (USA) which brings togethe...

Statens Serum Institut

Statens Serum Institut is a public enterprise operating as a market-oriented production and service enterprise.Statens Serum Institut is an enterprise under the Danish Ministry of the Interior and Hea...

Institut Pasteur

The Institut Pasteur is a non-profit foundation dedicated to the prevation and treatment of diseases through biological research,education and public health activites

More Information about "Institut Gustave Roussy" on BioPortfolio

We have published hundreds of Institut Gustave Roussy news stories on BioPortfolio along with dozens of Institut Gustave Roussy Clinical Trials and PubMed Articles about Institut Gustave Roussy for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Institut Gustave Roussy Companies in our database. You can also find out about relevant Institut Gustave Roussy Drugs and Medications on this site too.

Quick Search
Advertisement
 

Relevant Topics

Head and neck cancers
Cancer can occur in any of the tissues or organs in the head and neck. There are over 30 different places that cancer can develop in the head and neck area. Mouth cancers (oral cancers)  - Mouth cancer can develop on the lip, the tongue, the floor...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...


Corporate Database Quicklinks



Searches Linking to this Company Record